Cargando…

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance

Treatment with pan-genotypic direct-acting antivirals, targeting different viral proteins, is the best option for clearing hepatitis C virus (HCV) infection in chronically infected patients. However, the diversity of the HCV genome is a major obstacle for the development of antiviral drugs, vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuypers, Lize, Li, Guangdi, Libin, Pieter, Piampongsant, Supinya, Vandamme, Anne-Mieke, Theys, Kristof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584301/ https://www.ncbi.nlm.nih.gov/pubmed/26389941 http://dx.doi.org/10.3390/v7092857

Ejemplares similares

Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development
por: Cuypers, Lize, et al.
Publicado: (2016)

HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes
por: Li, Guangdi, et al.
Publicado: (2014)

A new ensemble coevolution system for detecting HIV-1 protein coevolution
por: Li, Guangdi, et al.
Publicado: (2015)

An integrated map of HIV genome-wide variation from a population perspective
por: Li, Guangdi, et al.
Publicado: (2015)

Zika genomics urgently need standardized and curated reference sequences
por: Theys, Kristof, et al.
Publicado: (2017)

Time to Harmonize Dengue Nomenclature and Classification
por: Cuypers, Lize, et al.
Publicado: (2018)

Functional conservation of HIV-1 Gag: implications for rational drug design
por: Li, Guangdi, et al.
Publicado: (2013)

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
por: Cuypers, Lize, et al.
Publicado: (2018)

Genome-wide diversity of Zika virus: Exploring spatio-temporal dynamics to guide a new nomenclature proposal
por: Seabra, Sofia G, et al.
Publicado: (2022)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context
por: Libin, Pieter, et al.
Publicado: (2017)

Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients
por: Marascio, Nadia, et al.
Publicado: (2016)

A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
por: Torneri, Andrea, et al.
Publicado: (2020)

Advances in Visualization Tools for Phylogenomic and Phylodynamic Studies of Viral Diseases
por: Theys, Kristof, et al.
Publicado: (2019)

A computational method for the identification of Dengue, Zika and Chikungunya virus species and genotypes
por: Fonseca, Vagner, et al.
Publicado: (2019)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Drivers of HIV-1 transmission: The Portuguese case
por: Pineda-Peña, Andrea-Clemencia, et al.
Publicado: (2019)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations
por: Pingarilho, Marta, et al.
Publicado: (2020)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

VIRULIGN: fast codon-correct alignment and annotation of viral genomes
por: Libin, Pieter J K, et al.
Publicado: (2019)

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response
por: Vercauteren, Jurgen, et al.
Publicado: (2013)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
por: Sahin, Ahmet, et al.
Publicado: (2023)

Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus
por: Simmonds, Peter, et al.
Publicado: (2020)

Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure
por: Rodrigues, João Paulo Vilela, et al.
Publicado: (2022)

A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences
por: Alcantara, Luiz Carlos Junior, et al.
Publicado: (2009)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis
por: Cooper, C., et al.
Publicado: (2013)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pklsgbj7uk0o1ujn2v99ah1p4h